The transplantation literature includes numerous papers that report associations between
polymorphisms in genes encoding metabolizing enzymes and drug transporters, and …

The patent of mycophenolate mofetil (MMF) has expired, and for enteric‐coated
mycophenolate sodium (EC‐MPS), this will happen in 2017. In the twenty years these drugs …

Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …

Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …

Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …

Introduction: Starting doses of tacrolimus and ciclosporin are typically chosen on a
calculated mg/kg bodyweight basis. After initiation of treatment, doses are adjusted with …

Lung transplant patients present important variability in immunosuppressant blood
concentrations during the first months after transplantation. Pharmacogenetics could explain …

The heterogeneous Brazilian population, with European, African and Amerindian ancestral
roots is a model case for exploring the impact of population admixture on the frequency …

Aims. The influence of interleukin‐10 (IL‐10) and interleukin‐18 (IL‐18) polymorphisms on
tacrolimus pharmacokinetics had been described in liver and kidney transplantation. The …

Background Renal dysfunction occurs commonly after heart transplantation (HT x) with wide
inter‐individual variability but whether a genetic predisposition exists in these patients is …